Stiftungsprofessur für Neuroimmunologie

Reallocation / Closing: 15/03/2018
Address:
Schwabachanlage 6
91054 Erlangen


Publications


Haase, S., Haghikia, A., Gold, R., & Linker, R. (2018). Dietary fatty acids and susceptibility to multiple sclerosis. Multiple sclerosis journal, 24(1), 12-16. https://dx.doi.org/10.1177/1352458517737372
Schmidt, M., Linker, R., Lang, S., Lücking, H., Engelhorn, T., Kloska, S.,... Dankerl, P. (2017). FLAIRfusion Processing with Contrast Inversion : Improving Detection and Reading Time of New Cerebral MS Lesions. Clinical Neuroradiology. https://dx.doi.org/10.1007/s00062-017-0567-y
Linker, R., & Wendt, G. (2016). Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study. Neurology and Therapy, 5(2), 193-201. https://dx.doi.org/10.1007/s40120-016-0051-7
Domenig, O., Manzel, A., Grobe, N., Koenigshausen, E., Kaltenecker, C.C., Kovarik, J.J.,... Poglitsch, M. (2016). Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney. Scientific Reports, 6, 33678. https://dx.doi.org/10.1038/srep33678
Joerg, S., Grohme, D.A., Erzler, M., Binsfeld, M., Haghikia, A., Mueller, D.N.,... Kleinewietfeld, M. (2016). Environmental factors in autoimmune diseases and their role in multiple sclerosis. Cellular and Molecular Life Sciences, 73(24), 4611-4622. https://dx.doi.org/10.1007/s00018-016-2311-1
Binger, K.J., Gebhardt, M., Heinig, M., Rintisch, C., Schröder, A., Neuhofer, W.,... Mueller, D.N. (2015). High salt reduces the activation of IL-4- and IL-13-stimulated macrophages. Journal of Clinical Investigation, 125(11), 4223-38. https://dx.doi.org/10.1172/JCI80919
Binger, K.J., Linker, R., Muller, D.N., & Kleinewietfeld, M. (2015). Sodium chloride, SGK1, and Th17 activation. Pflugers Archiv-European Journal of Physiology, 467(3), 543-50. https://dx.doi.org/10.1007/s00424-014-1659-z
Linker, R. (2015). Zeigen die neuen oralen Therapien Vorteile in der Basistherapie der Multiplen Sklerose? Kontra. Der Nervenarzt, 86(4), 492-4. https://dx.doi.org/10.1007/s00115-014-4246-9

Last updated on 2019-24-04 at 17:57